1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Local Anesthesia Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Lidocaine
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Bupivacaine
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Benzocaine
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Ropivacaine
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Prilocaine
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Chloroprocaine
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Mode of Administration
7.1 Injectables
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Surface Anesthetic
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pharmacy Stores
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Aspen Pharmacare Holdings Limited
14.3.1.1 Company Overview
14.3.1.2 Drug Type Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 B. Braun Melsungen AG
14.3.2.1 Company Overview
14.3.2.2 Drug Type Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Baxter International Inc.
14.3.3.1 Company Overview
14.3.3.2 Drug Type Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Endo International plc
14.3.4.1 Company Overview
14.3.4.2 Drug Type Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Fresenius SE & Co. KGaA
14.3.5.1 Company Overview
14.3.5.2 Drug Type Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Hikma Pharmaceuticals plc
14.3.6.1 Company Overview
14.3.6.2 Drug Type Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Pacira Biosciences Inc.
14.3.7.1 Company Overview
14.3.7.2 Drug Type Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Drug Type Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Pierrel S.p.A.
14.3.9.1 Company Overview
14.3.9.2 Drug Type Portfolio
14.3.9.3 Financials
14.3.10 Septodont
14.3.10.1 Company Overview
14.3.10.2 Drug Type Portfolio
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer